<- Go Home
enGene Holdings Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Market Cap
$550.9M
Volume
122.8K
Cash and Equivalents
$32.6M
EBITDA
-$101.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$11.14
52 Week Low
$2.65
Dividend
N/A
Price / Book Value
2.17
Price / Earnings
-4.45
Price / Tangible Book Value
2.17
Enterprise Value
$380.3M
Enterprise Value / EBITDA
-3.80
Operating Income
-$101.1M
Return on Equity
43.95%
Return on Assets
-24.67
Cash and Short Term Investments
$201.9M
Debt
$31.4M
Equity
$200.7M
Revenue
N/A
Unlevered FCF
-$58.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium